Oxytocin: Structure, the Disulfide Bridge, and the Research Literature

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

Oxytocin is a nine-residue peptide with a single disulfide bridge, the first peptide hormone ever sequenced and synthesized in a laboratory, and a molecule that exists as an approved drug product under the name Pitocin. This article covers the chemistry of the cysteine bridge, the relationship to vasopressin, what the receptor structures published between 1992 and 2025 show, how the peptide degrades in solution, and why a research vial is not the approved drug.

What oxytocin is: a nonapeptide with a 20-membered ring

Oxytocin is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, with a disulfide bond between the cysteines at positions 1 and 6. The formula is C₄₃H₆₆N₁₂O₁₂S₂, the molecular weight 1007.2, PubChem CID 439302, CAS 50-56-6. The Cys¹-Cys⁶ bridge closes six residues into a 20-membered ring, sometimes called the tocin ring, and leaves a three-residue tail (Pro-Leu-Gly-NH₂) ending in a glycinamide. The ring and the amidated tail are the two structural features that define the whole neurohypophysial family, and both are required for receptor recognition.

The sequence was established by Vincent du Vigneaud's group at Cornell, who reported the amino-acid order and proposed the cyclic structure in the Journal of Biological Chemistry in 1953 and achieved total synthesis the same year. That synthesis was the first of any peptide hormone and earned the 1955 Nobel Prize in Chemistry; it is also the reason synthetic oxytocin, rather than extract-derived material, has been the pharmaceutical form for seven decades. Reading the sequence requires two conventions covered in how to read a peptide sequence: the bracket or line notation for the disulfide, and the -NH₂ suffix for the C-terminal amide.

Oxytocin and vasopressin: two residues apart

Oxytocin and arginine vasopressin differ at only two of nine positions. Position 3 is isoleucine in oxytocin and phenylalanine in vasopressin; position 8 is leucine in oxytocin and arginine in vasopressin. Everything else, including the disulfide ring and the amidated glycine, is shared. Roger Acher's comparative work, summarized in a 1967 Nature paper on the phylogeny of the neurohypophysial hormones, showed that the two mammalian peptides sit within a larger family of ring-and-tail nonapeptides found across vertebrates, with vasotocin (Ile³, Arg⁸) as the likely ancestral form from which both lineages diverged.

The practical consequence for analytics is that oxytocin and vasopressin have nearly identical hydrophobic ring structures and similar masses (1007.2 versus 1084.2), elute close together on reverse-phase HPLC, and share four receptors in a single family. A certificate must therefore confirm identity by mass, not by retention time alone; the LC-MS identity article explains why the 77-dalton difference is decisive where a chromatogram is not.

The oxytocin receptor: cloning, cholesterol and magnesium

The human oxytocin receptor (OTR, gene OXTR) was cloned by expression cloning in Xenopus oocytes and reported by Kimura and colleagues in Nature in 1992. It encodes a 388-residue protein with seven transmembrane helices, the hallmark of a G protein-coupled receptor, and the oocyte assay showed an inward membrane current specifically in response to oxytocin. The receptor couples primarily through G_q/11 to phospholipase C and calcium release, and it belongs to the same subfamily as the three vasopressin receptors (V1a, V1b and V2), which is why ligand selectivity within the family has been a decades-long medicinal-chemistry problem. The GPCR primer covers the shared mechanics.

Two unusual requirements of the receptor were characterized in cell and membrane work long before any structure existed. Gimpl and Fahrenholz's 2001 Physiological Reviews survey documented that high-affinity agonist binding depends on divalent cations, with magnesium the most effective, and on membrane cholesterol; Gimpl's 2008 follow-up in Progress in Brain Research described cholesterol as an allosteric modulator that stabilizes the receptor in a high-affinity state. These were biochemical observations on membrane preparations and transfected cells, and they framed the questions the structural papers later answered.

Receptor structures, 2020 to 2025

Three structural papers now explain the cation and cholesterol dependence at atomic level. Waltenspühl and colleagues reported the first crystal structure of the human receptor in Science Advances in 2020, in complex with the non-peptide antagonist retosiban. The structure showed a cholesterol molecule bound outside the helical bundle between helices IV and V, giving a physical basis for the allosteric effect, and identified a conserved coordination site for Mg²⁺ that acts as a positive allosteric modulator of agonist binding.

Meyerowitz and colleagues then reported the active-state cryo-EM structure of wild-type receptor bound to oxytocin and a mini-G_q/i protein in Nature Structural and Molecular Biology in 2022. The structure showed the peptide and the receptor jointly coordinating a magnesium ion, and the peptide displacing part of transmembrane helix 7 on binding. In functional assays, that TM7 disruption distinguished full agonism by oxytocin from partial agonism by analogs, and the authors showed that a single cation-coordinating residue determines whether a given vasopressin-family receptor is cation-dependent at all. A 2025 Biophysical Journal study by Marlow and colleagues extended the picture with a biophysical and computational analysis of cholesterol's allosteric modulation of the receptor.

For a research lab, the practical reading is that any binding or signaling assay with oxytocin is sensitive to the magnesium content of the buffer and the cholesterol content of the membrane preparation, and that results from different papers are only comparable when those conditions match.

Degradation in solution: what the stability papers measured

Oxytocin is a well-characterized example of a peptide that is stable as a dry lyophilizate and unstable in water, and the degradation chemistry has been mapped in detail because the drug product is supplied as a solution. Hawe and colleagues reported in Pharmaceutical Research in 2009 an accelerated-stability study at pH 2.0, 4.5, 7.0 and 9.0 and temperatures from 40 to 80 degrees Celsius, following loss of intact peptide by reverse-phase HPLC and identifying products by tandem mass spectrometry. Loss followed pseudo-first-order kinetics, was slowest at pH 4.5 and fastest at pH 9.0, and fitted the Arrhenius equation with the highest activation energy (116 kJ/mol) at pH 4.5. At pH 2 the main products were deamidated species at Gln⁴, Asn⁵ and the C-terminal Gly-NH₂. At pH 4.5 and above, the disulfide became the weak point: tri- and tetrasulfide forms, disulfide-linked and dityrosine-linked dimers, beta-elimination products and larger aggregates all appeared.

Avanti and colleagues followed in the AAPS Journal in 2011 with a formulation study showing that citrate buffer at pH 4.5 combined with at least 2 mM calcium, magnesium or zinc chloride improved stability over four weeks at both 4 and 55 degrees Celsius, whereas acetate buffer with the same ions did not; isothermal titration calorimetry showed a measurable peptide-ion interaction only in the citrate system. Both papers are formulation chemistry, not usage guidance, and they explain three things a lab should expect: the HPLC chromatogram of an aged oxytocin solution gains early-eluting deamidation peaks and late-eluting dimer peaks; a mass spectrum may show +32 or +64 dalton species from extra sulfur; and buffer pH and divalent-ion content are the variables that set the rate. The spray formulation and aliquot and oxidation articles apply those principles.

Approval history and why a research vial is not Pitocin

Synthetic oxytocin is approved by the FDA as Pitocin; the application currently listed in Drugs@FDA, NDA 018261, was approved in November 1980, and oxytocin is also marketed under generic approved applications. One detail of the drug labeling is worth understanding as unit chemistry: the approved product is labeled in USP units of activity per milliliter rather than in milligrams, because oxytocin potency has historically been defined by bioassay against a USP reference standard. A research vial, by contrast, is labeled by lyophilized mass, and its certificate reports net peptide content by analytical methods, not units of activity. The two numbering systems are not interchangeable, and no research certificate reports USP units.

A lyophilized or liquid oxytocin research product is not Pitocin, not a generic oxytocin drug, and not a compounded preparation. It is a laboratory reagent: synthesized and lyophilized in the USA, characterized by an independent US laboratory, and supplied under a research-use-only attestation. For Oxytocin 2 mg and Oxytocin 10 mg, the lot-matched certificate reports identity by mass spectrometry against the oxidized (disulfide-closed) mass of 1007.2, purity by HPLC, net peptide content, endotoxin, sterility and heavy metals. The Oxytocin liquid spray 10 mg (10 mL) is documented by total labeled mass per bottle and buffer composition, which, given the stability data above, is the line to read first. The FDA status table records oxytocin as "approved as Pitocin and generics; research vial is not that product."

Frequently Asked Questions

What is the disulfide bridge in oxytocin?

Oxytocin's two cysteines, at positions 1 and 6, are joined by a disulfide bond that closes the first six residues into a 20-membered ring. The ring plus the amidated three-residue tail is the shared architecture of the whole neurohypophysial peptide family, and breaking the bridge by reduction abolishes receptor binding.

How is oxytocin different from vasopressin?

They differ at two positions: oxytocin has isoleucine at position 3 and leucine at position 8, while arginine vasopressin has phenylalanine and arginine there. Their masses differ by 77 daltons (1007.2 versus 1084.2), which is how mass spectrometry tells them apart; HPLC retention alone is not a reliable discriminator.

Is oxytocin approved by the FDA?

Yes. Synthetic oxytocin is approved by the FDA as Pitocin (NDA 018261) and as generic oxytocin drug products, labeled in USP units. A research-grade oxytocin vial or liquid spray is not Pitocin and is not an approved drug; it is a laboratory reagent labeled by mass.

Why does oxytocin degrade in solution?

A 2009 Pharmaceutical Research study found that oxytocin in water deamidates at Gln⁴, Asn⁵ and the C-terminal glycinamide at low pH, and forms trisulfide, tetrasulfide, dimer and aggregate species through its disulfide at pH 4.5 and above, with the slowest loss at pH 4.5. Lyophilized powder stored cold and dry avoids both pathways.

Citations

1. du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem. 1953;205:949-957. PMID 13129273
2. Acher R, Chauvet J, Chauvet MT, Crepy D. Phylogeny of the neurohypophysial hormones. Nature. 1967;216:1037-1038. PMID 6066559
3. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature. 1992;356:526-529. PMID 1313946
4. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629-683. PMID 11274341
5. Gimpl G, Reitz J, Brauer S, Trossen C. Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res. 2008;170:193-204. PMID 18655883
6. Hawe A, Poole R, Romeijn S, Kasper P, van der Heijden R, Jiskoot W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res. 2009;26:1679-1688. PMID 19343484
7. Avanti C, Amorij JP, Setyaningsih D, et al. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011;13:284-290. PMID 21448747
8. Waltenspühl Y, Schöppe J, Ehrenmann J, Kummer L, Plückthun A. Crystal structure of the human oxytocin receptor. Sci Adv. 2020;6:eabb5419. PMID 32832646
9. Meyerowitz JG, Robertson MJ, Barros-Álvarez X, et al. The oxytocin signaling complex reveals a molecular switch for cation dependence. Nat Struct Mol Biol. 2022;29:274-281. PMID 35241813
10. Marlow B, Vogel A, et al. Cholesterol allosteric modulation of the oxytocin receptor. Biophys J. 2025;124:1930-1943. PMID 40308029
11. US FDA. Drugs@FDA: NDA 018261, Pitocin (oxytocin). Drugs@FDA
12. PubChem. Oxytocin, CID 439302. PubChem

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.